血清素免疫反应阳性胰腺神经内分泌肿瘤伴主胰管扩张:可识别的实体且长期预后良好
本回顾性研究纳入60例伴主胰管扩张(≥4 mm)的胰腺神经内分泌肿瘤(panNEN),比较血清素免疫反应阳性(S+)与阴性(S-)的影像和病理特征及预后。S+ panNEN更小(中位12.5 mm vs 33 mm)、门静脉期强化更明显(95% vs 25%)、纤维间质更丰富,且无复发生存期显著更长。肿瘤大小≤20 mm诊断S+ panNEN的敏感度95%、特异度90%。
要点
- 伴主胰管扩张的panNEN若肿瘤≤20 mm且门静脉期持续强化,应提示血清素阳性可能。
- S+ panNEN纤维间质丰富、微血管密度高、Ki-67低,长期无复发预后好。
- S- panNEN更易复发,中位无复发生存期31.3个月,需密切随访。
关键影像表现/征象
- S+ panNEN中位大小12.5 mm,S-为33 mm(p < 0.01)。
- S+ panNEN在CT/MRI门静脉期呈高密度/高信号者占95%,S-为25%(p < 0.01)。
- S+ panNEN病理纤维间质比例60.7 ± 16%,S-为40.7 ± 12.8%(p < 0.01)。
诊断标准与关键数值
- 肿瘤大小≤20 mm诊断S+ panNEN的敏感度95%、特异度90%。
- 多因素分析中肿瘤大小是唯一与S+ panNEN相关的影像因素。
临床应用与阅片要点
- 阅片时对伴主胰管扩张的小panNEN(≤20 mm)应关注门静脉期强化程度,提示血清素免疫反应阳性可能。
- S+ panNEN预后良好,可避免过度治疗;S- panNEN复发风险高,需加强随访。
局限性
- 回顾性研究,样本量60例,可能存在选择偏倚。
- 单中心研究,结果需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Dilatation of the main pancreatic duct (MPD) is rare in pancreatic neuroendocrine neoplasm (panNEN) and may be due to different mechanisms. We compared the imaging and pathological characteristics as well as the outcome after resection of positive (S+) and negative (S-) serotonin immunoreactive panNENs causing MPD dilatation.
METHODS: This retrospective study included patients with panNEN, with MPD dilatation (≥ 4 mm) on preoperative CT/MRI and resected between 2005 and 2019. Clinical, radiological, and pathological features were compared between S+ and S- panNENs. Imaging features associated with S+ panNEN were identified using logistic regression analysis. The diagnostic performance of imaging for the differentiation of S+ and S- panNENs was assessed by ROC curve analysis. Recurrence-free survival (RFS) was compared between the two groups.
RESULTS: The final population of 60 panNENs included 20/60 (33%) S+ panNENs. S+ panNENs were smaller (median 12.5 mm vs. 33 mm; p < 0.01), more frequently hyperattenuating/intense on portal venous phase at CT/MRI (95% vs. 25%, p < 0.01), and presented with more fibrotic stroma on pathology (60.7 ± 16% vs. 40.7 ± 12.8%; p < 0.01) than S- panNENs. Tumor size was the only imaging factor associated with S+ panNEN on multivariate analysis. A tumor size ≤ 20 mm had 95% sensitivity and 90% specificity for the diagnosis of S+ panNEN. Among 52 patients without synchronous liver metastases, recurrence occurred in 1/20 (5%) with S+ panNEN and 18/32 (56%) with S- panNEN (p < 0.01). Median RFS was not reached in S+ panNENs and was 31.3 months in S- panNENs (p < 0.01).
CONCLUSIONS: In panNENs with MPD dilatation, serotonin positivity is associated with smaller size, extensive fibrotic stroma, and better long-term outcomes.
KEY POINTS: • S+ panNENs showed a higher percentage of fibrotic stroma, higher microvessel density, and lower proliferation index (Ki-67) compared to S- panNENs. • Radiologically, S+ panNENs causing dilatation of the MPD were characterized by a small size (< = 20 mm) and a persistent enhancement on portal phase on both CT and MRI. • Patients with S+ panNENs presented with longer RFS when compared to those with S- panNENs.
引用
- Dioguardi Burgio M, Cros J, Panvini N, et al. Serotonin immunoreactive pancreatic neuroendocrine neoplasm associated with main pancreatic duct dilation: a recognizable entity with excellent long-term outcome. Eur Radiol. 2021. PMID: 33977308. doi:10.1007/s00330-021-08007-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。